BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company’s lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
तुलना करने के लिए मीट्रिक्स | BCAB | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधBCABपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −0.2x | −3.0x | −0.5x | |
PEG अनुपात | −0.01 | 0.33 | 0.00 | |
क़ीमत/बुक | −0.4x | 5.0x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 10.8x | 3.3x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 69.8% | 46.2% | |
उचित मूल्य अपसाइड | अनलॉक करें | 2.1% | 6.6% | अनलॉक करें |